WO2005082373A1 - ユージストミン誘導体医薬組成物 - Google Patents
ユージストミン誘導体医薬組成物 Download PDFInfo
- Publication number
- WO2005082373A1 WO2005082373A1 PCT/JP2005/003106 JP2005003106W WO2005082373A1 WO 2005082373 A1 WO2005082373 A1 WO 2005082373A1 JP 2005003106 W JP2005003106 W JP 2005003106W WO 2005082373 A1 WO2005082373 A1 WO 2005082373A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- pharmaceutical composition
- therapeutic agent
- composition according
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
Definitions
- the present invention relates to a pharmaceutical composition useful as an antitumor agent ⁇ antiviral agent.
- Eudistomins having a skeleton in which a tetrahydro- ⁇ -carboline ring and an oxathiazepane ring are fused are known to exhibit strong antitumor activity ⁇ ⁇ antiviral activity (Non-patent Reference).
- Eudistomins have a unique structure in which a 6_5_6_7-membered ring is condensed and has a ⁇ -0_C—S bond in a 7-membered ring portion as shown by the above general formula ( ⁇ ). Therefore, only synthetic examples of several kinds of natural products and derivatives thereof have been reported (see Non-Patent Documents 3 and 4 and Patent Documents 2 and 3).
- Non-Patent Document 1 Journal of American Chemical Society, 109, 3378 (1987)
- Non-Patent Document 2 Australian Journal of Chemistry, 42, 1201 (1989)
- Non-Patent Document 3 Journal of Medicinal Chemistry, 35, 3223 (1992)
- Non-Patent Document 4 Bioorganic & Medicinal Chemistry, 5, 955 (1997)
- Patent Document 1 JP-A-60-100576
- Patent Document 2 Japanese Patent Application Laid-Open No. Hei 3-68582
- Patent Document 3 JP-A-2002-363180
- Patent Document 3 The present inventors have previously reported on Patent Document 3 the synthesis of a eudystomin derivative having a substituent that is not found in natural eudystomins. While they have the raw Physiological activity has not been known so far.
- R represents a hydroxyl group, an aryloxy group, a methylsulfonyloxy group, or a p-methoxyphenyl group.
- Salts of eudystomin derivatives include, for example, mineral salts such as hydrochloride, hydrobromide, sulfate, nitrate and phosphate; methanesulfonate, benzenesulfonate and paratoluenesulfonate Sulphonates such as acetate, propionate, tartrate, fumarate, maleate, malate, oxalate, succinate, citrate, benzoate, mandelic acid, calcium Carboxylates such as cinnamate and lactate are exemplified.
- mineral salts such as hydrochloride, hydrobromide, sulfate, nitrate and phosphate
- methanesulfonate, benzenesulfonate and paratoluenesulfonate Sulphonates such as acetate, propionate, tartrate, fumarate, maleate, malate, oxalate, succinate, citrate, benzoate
- the eudystomin derivative represented by the general formula (I) can be produced by the method described in Patent Document 3 or a method analogous thereto.
- the salts thereof, or hydrates or solvates thereof may be produced by a known method of the eudystomin derivative.
- the eudystomin derivative represented by the general formula (I) has an antitumor activity and an antiviral activity, and thus can be used as an antitumor agent or an antiviral agent.
- the eudystomin derivative in the present invention has a strong antitumor activity and can be used as an antitumor agent.
- target cancer types include solid cancers such as breast cancer, lung cancer, stomach cancer, colon cancer, knee and brain tumors; and blood cancers such as leukemia.
- the eudystomin derivative in the present invention has strong antiviral activity, it can be used as an antiviral agent.
- Targeted viruses include anti-DNA viruses such as herpes virus, cytomegalovirus, and papilloma virus; anti-DNA viruses such as hepatitis C virus, influenza virus, coronavirus, severe acute respiratory syndrome virus, rabies virus, and norovirus.
- RNA viruses can be mentioned.
- the pharmaceutical composition according to the present invention comprises the eudystomin derivative represented by the general formula (I) or a salt thereof, or a hydrate or solvate thereof, and a conventional pharmaceutical carrier in an appropriate ratio. After mixing, it can be prepared by treating in a conventional manner.
- Pharmaceutical carriers include, for example, excipients such as glucose, lactose, D-mannitol, starch and crystalline cellulose; disintegrants or disintegrants such as carboxymethylcellulose, starch or calcium carboxymethylcellulose; hydroxypropylcellulose Binders such as hydroxypropyl methylcellulose, polyvinylpyrrolidone or gelatin; lubricants such as magnesium stearate or talc; coating agents such as hydroxypropylmethyl cellulose, sucrose, polyethylene glycol or titanium oxide; petrolatum, liquid paraffin, polyethylene Base such as glyconore, gelatin, kaolin, glycerin, purified water or hard fat; aqueous or ready-to-use injection such as distilled water for injection, physiological saline or propylene glycol.
- excipients such as glucose, lactose, D-mannitol, starch and crystalline cellulose
- disintegrants or disintegrants such as carboxymethylcellulose, starch or calcium carboxymethylcellulose
- Dissolving agents or solubilizing agents that can be used; isotonic agents such as glucose, sodium chloride, D-mannitol, or glycerin; pH regulators such as inorganic acids, organic acids, inorganic bases or organic bases; pigments; A stabilizer; a propellant and an adhesive.
- the preparation containing the pharmaceutical composition according to the present invention may be appropriately selected according to the administration method.
- oral administration tablets, granules, fine granules, powders , Hard capsules, soft capsules, syrups, liquids, emulsions, suspensions, elixirs, etc.
- parenteral administration injections, eye drops, nasal drops, ointments, eyes Ointments, suppositories, and the like.
- Human breast cancer cell line MDA-MB-157 prepared in D-MEM (No. D6046, manufactured by Sigma) containing 10% fetal serum (No. F9423, manufactured by Sigma) was used in 96-well plates (Asahi Techno Glass Co., Ltd.) Was seeded at a rate of 2,000 per well and 0.05 mL. The next day, the DMSO lysate of the test substance was diluted to twice the final concentration with D-MEM containing 10% fetal bovine serum, and added to the cells seeded the day before at a rate of 0.05 mL / per microliter. Three days later, Cell Counting Kit reagent (No.
- IFN a human recombinant interferon a
- RNA of HCV-replicon was quantified.
- ABI PRISM7900 manufactured by Applied Biosystems was used as an apparatus, and quantification was performed according to the method of Takeuchi et al. (Gastroenterology 116, 636 (1999)).
- RNA subjected to lume extraction and ethanol precipitation was used as RNA for a standard curve for quantitative PCR. In the above quantitative PCR, it was confirmed that linearity was obtained over 10 2 to 10 8 .
- the IC was 4.8 (IU / mL) for IFN a and 8.4 (nM) for the test compound, respectively.
- the pharmaceutical composition according to the present invention exhibits antitumor activity and antiviral activity, and thus can be used as an antitumor agent or an antiviral agent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-054701 | 2004-02-27 | ||
JP2004054701 | 2004-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005082373A1 true WO2005082373A1 (ja) | 2005-09-09 |
Family
ID=34908802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003106 WO2005082373A1 (ja) | 2004-02-27 | 2005-02-25 | ユージストミン誘導体医薬組成物 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005082373A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60100576A (ja) * | 1983-07-25 | 1985-06-04 | ザ ボ−ドオブトラステイ−ズ オブ ザ ユニバ−シテイ オブ イリノイズ | 海洋被嚢類からの抗ビ−ルス性ユ−ジストミン類 |
JPH0368582A (ja) * | 1989-06-08 | 1991-03-25 | Duphar Internatl Res Bv | N―オキソ―テトラヒドロ―β―カルボリンおよびその製造方法 |
JP2002363180A (ja) * | 2001-06-05 | 2002-12-18 | Japan Science & Technology Corp | ユーディストミン合成中間体およびその合成方法 |
-
2005
- 2005-02-25 WO PCT/JP2005/003106 patent/WO2005082373A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60100576A (ja) * | 1983-07-25 | 1985-06-04 | ザ ボ−ドオブトラステイ−ズ オブ ザ ユニバ−シテイ オブ イリノイズ | 海洋被嚢類からの抗ビ−ルス性ユ−ジストミン類 |
JPH0368582A (ja) * | 1989-06-08 | 1991-03-25 | Duphar Internatl Res Bv | N―オキソ―テトラヒドロ―β―カルボリンおよびその製造方法 |
JP2002363180A (ja) * | 2001-06-05 | 2002-12-18 | Japan Science & Technology Corp | ユーディストミン合成中間体およびその合成方法 |
Non-Patent Citations (2)
Title |
---|
LAKE R. ET AL.: "Eudistomis from the new zealand ascidian ritterella sigillinoides.", JOURNAL OF CHEMISTRY., vol. 42, no. 7, 1989, pages 1201 - 1206, XP002988793 * |
VAN MAARSEVEEN H.J. ET AL.: "Antiviral and tumor cell antiproliferatives SAR studies on tetracyclic eudistomins-II.", BIOORGANIC AND MEDICINE CHEMISTRY., vol. 5, no. 5, 1997, pages 955 - 970, XP002988792 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9044432B2 (en) | Compositions and methods for cancer detection and treatment | |
US20230000893A1 (en) | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | |
US20110082208A1 (en) | Therapies for cancer using isotopically substituted lysine | |
CN116802180B (zh) | 一种降解脱氧核糖核酸(dna)聚合酶的化合物及其用途 | |
CN111743899B (zh) | 硝唑尼特及其活性形式替唑尼特在制备用于治疗SARS-CoV-2感染的药物中的应用 | |
ES2383534T3 (es) | Polimorfos de di-N-metil-D-glucamina del ácido 3-O-(3',3'-dimetilsuccinil)betulínico | |
WO2024008129A1 (zh) | 作为kat6抑制剂的化合物 | |
EP2597097A1 (en) | Substituted indoles, antiviral active component, method for producing and using same | |
TWI831999B (zh) | 一種西達本胺藥物組合物及其應用 | |
JPH09165336A (ja) | 癌疾患治療におけるイソオキサゾールおよびクロトンアミド誘導体の使用 | |
US9511064B2 (en) | Combination therapy for the treatment of cancer and immunosuppression | |
EP3189064B1 (en) | Platinum (iv) complex with increased antitumor efficacy | |
WO2005082373A1 (ja) | ユージストミン誘導体医薬組成物 | |
US20220177469A1 (en) | Solid forms of emetine | |
WO1997037661A1 (fr) | Medicament de prevention et de traitement des infections virales | |
CN111484541B (zh) | 双核苷酸前体药物及其制备方法 | |
WO2018157742A1 (zh) | Sb-939的盐的晶型及其制备方法和用途 | |
WO1997036904A1 (fr) | Derive de la mitomycine c et inhibiteur des tyrosine kinases non receptrices | |
US20240228485A1 (en) | Solid forms of emetine | |
CN113292448B (zh) | 一种茚酮类亚胺衍生物及其制备方法与应用 | |
US20240216414A1 (en) | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | |
WO2004080453A1 (ja) | 抗c型肝炎ウイルス剤と抗hiv剤 | |
CN115286574B (zh) | Blvrb酶功能抑制剂及其制备方法和用途 | |
WO2022237710A1 (zh) | 治疗流感化合物的晶型及应用 | |
EP4000620A1 (en) | Lactam and lactone derivatives for use in the treatment of a viral infection such as covid-19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |